This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio - its third in five months - as it tries to chase down Pfizer’s category-leading Ibrance. ... year and is predicted to become a $6bn product at peak by EvaluatePharma - as
show that a CDK4/6 inhibitor can have a benefit in this setting. ... Meanwhile Novartis is trying to keep its new drug ahead of Eli Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib), which was approved in the US - its first market - last September.
New phase III data for Novartis’CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women. ... Novartis is currently a little ahead of Eli Lilly, whose CDK4/6 inhibitor Verzenio (abemaciclib) was approved
The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival ... This is a clinically relevant proportion of patients
trial, which showed that the drug was superior to the widely-used aromatase inhibitor anastrozole as a first-line treatment. ... While other drugs such as Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and Novartis' rival Kisqali (ribociclib) "may yet
Novartis claims EU approval for breast cancer drug Kisqali. Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe. ... Novartis can now challenge Pfizer's blockbuster breast cancer drug Ibrance in Europe after gaining approval for its
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...